1. Home
  2. STTK vs DCGO Comparison

STTK vs DCGO Comparison

Compare STTK & DCGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.05

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Logo DocGo Inc.

DCGO

DocGo Inc.

HOLD

Current Price

$0.90

Market Cap

97.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STTK
DCGO
Founded
2016
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Managed Health Care
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
119.0M
97.4M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
STTK
DCGO
Price
$3.05
$0.90
Analyst Decision
Buy
Strong Buy
Analyst Count
5
3
Target Price
$4.00
$3.33
AVG Volume (30 Days)
392.9K
687.1K
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,000,000.00
$368,093,385.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.69
$0.87
52 Week High
$3.38
$5.68

Technical Indicators

Market Signals
Indicator
STTK
DCGO
Relative Strength Index (RSI) 67.21 36.60
Support Level $2.82 $0.88
Resistance Level $3.30 $0.99
Average True Range (ATR) 0.24 0.06
MACD -0.00 -0.00
Stochastic Oscillator 74.76 1.38

Price Performance

Historical Comparison
STTK
DCGO

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About DCGO DocGo Inc.

DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has three reporting segments: Mobile Health Services, Transportation Services, and Corporate. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.

Share on Social Networks: